文献速递系统性红斑狼疮其他结缔组织病

Povetacicept:一种增强型双重APRIL/BAFF拮抗剂,可调节B淋巴细胞及致病性自身抗体,用于治疗狼疮和其他B细胞相关自身免疫病

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases.
PubMed 文献 · Arthritis Rheumatol · 2023-04-19

本研究通过定向进化获得高亲和力APRIL/BAFF双重拮抗剂povetacicept(ALPN-303),在体外及多种小鼠模型和非人灵长类中与野生型TACI-Fc及相关分子比较。结果显示povetacicept能更有效抑制B细胞增殖、分化和免疫球蛋白分泌,在狼疮肾炎模型中显著改善生存并抑制蛋白尿及肾损伤指标。

要点

  • Povetacicept在体外能强效抑制B细胞增殖、分化和免疫球蛋白分泌。
  • 在NZB×NZW狼疮肾炎小鼠中,povetacicept显著提高生存率并抑制蛋白尿和抗dsDNA抗体。
  • 在非人灵长类中单次给药后povetacicept耐受良好并显著降低血清IgM、IgA和IgG水平。

核心结论

  • Povetacicept增强的APRIL和BAFF抑制比野生型TACI-Fc及CD20、APRIL或BAFF选择性抑制剂更有效地抑制对自身抗体产生关键的B细胞群体。
  • Povetacicept强效的双重抑制有潜力显著改善自身抗体相关自身免疫病的临床结局。

研究设计与样本

  • 研究通过定向进化生成TACI-Fc变体,命名为povetacicept(ALPN-303),并在体外和体内与野生型TACI-Fc及相关分子进行比较。
  • 体内研究使用小鼠免疫模型、NZB×NZW小鼠狼疮肾炎模型、bm12小鼠狼疮模型以及非人灵长类。

主要发现

  • 在基于细胞的报告基因实验和原代人B细胞实验中,povetacicept比所有评估的野生型TACI-Fc形式及选择性APRIL和BAFF抑制剂更有效地抑制APRIL和BAFF,强效抑制B细胞增殖、分化和免疫球蛋白分泌。
  • 在小鼠免疫模型中,povetacicept比抗CD20单克隆抗体、野生型TACI-Fc或APRIL和BAFF抑制剂更有效地显著降低血清免疫球蛋白滴度和抗体分泌细胞。
  • 在NZB×NZW小鼠狼疮肾炎模型中,povetacicept显著提高生存率并抑制蛋白尿、抗双链DNA抗体滴度、血尿素氮、肾小球肾炎和肾脏免疫球蛋白沉积。
  • 在bm12小鼠狼疮模型中,povetacicept显著减少脾脏浆母细胞、滤泡辅助T细胞和生发中心B细胞。
  • 在非人灵长类中,povetacicept耐受良好,表现出高血清暴露,单次给药后显著降低血清IgM、IgA和IgG水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dysregulated APRIL/BAFF signaling is implicated in the pathogenesis of multiple autoimmune diseases, including systemic lupus erythematosus and lupus nephritis. We undertook this study to develop and evaluate a high-affinity APRIL/BAFF antagonist to overcome the clinical limitations of existing B cell inhibitors. METHODS: A variant of TACI-Fc generated by directed evolution showed enhanced binding for both APRIL and BAFF and was designated povetacicept (ALPN-303). Povetacicept was compared to wild-type (WT) TACI-Fc and related molecules in vitro and in vivo. RESULTS: Povetacicept inhibited APRIL and BAFF more effectively than all evaluated forms of WT TACI-Fc and selective APRIL and BAFF inhibitors in cell-based reporter assays and primary human B cell assays, mediating potent suppression of B cell proliferation, differentiation, and immunoglobulin (Ig) secretion. In mouse immunization models, povetacicept significantly reduced serum immunoglobulin titers and antibody-secreting cells more effectively than anti-CD20 monoclonal antibodies, WT TACI-Fc, or APRIL and BAFF inhibitors. In the NZB × NZW mouse lupus nephritis model, povetacicept significantly enhanced survival and suppressed proteinuria, anti-double-stranded DNA antibody titers, blood urea nitrogen, glomerulonephritis, and renal immunoglobulin deposition. In the bm12 mouse lupus model, povetacicept significantly reduced splenic plasmablasts, follicular helper T cells, and germinal center B cells. In non-human primates, povetacicept was well tolerated, exhibited high serum exposure, and significantly decreased serum IgM, IgA, and IgG levels after a single dose. CONCLUSION: Enhanced APRIL and BAFF inhibition by povetacicept led to greater inhibition of B cell populations critical for autoantibody production compared to WT TACI-Fc and CD20-, APRIL-, or BAFF-selective inhibitors. Potent, dual inhibition by povetacicept has the potential to significantly improve clinical outcomes in autoantibody-related autoimmune diseases.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Evans LS, Lewis KE, DeMonte D, et al. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. Arthritis Rheumatol. 2023. PMID: 36705554. doi:10.1002/art.42462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。